BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McDowell KA, Hadjimarkou MM, Viechweg S, Rose AE, Clark SM, Yarowsky PJ, Mong JA. Sleep alterations in an environmental neurotoxin-induced model of parkinsonism. Exp Neurol 2010;226:84-9. [PMID: 20713046 DOI: 10.1016/j.expneurol.2010.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Mizrahi-Kliger AD, Feldmann LK, Kühn AA, Bergman H. Etiologies of insomnia in Parkinson's disease - Lessons from human studies and animal models. Exp Neurol 2022;350:113976. [PMID: 35026228 DOI: 10.1016/j.expneurol.2022.113976] [Reference Citation Analysis]
2 Van Kampen JM, Robertson HA. The BSSG rat model of Parkinson's disease: progressing towards a valid, predictive model of disease. EPMA J 2017;8:261-71. [PMID: 29021837 DOI: 10.1007/s13167-017-0114-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
3 Pierozan P, Andersson M, Brandt I, Karlsson O. The environmental neurotoxin β-N-methylamino-L-alanine inhibits melatonin synthesis in primary pinealocytes and a rat model. J Pineal Res 2018;65:e12488. [PMID: 29528516 DOI: 10.1111/jpi.12488] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Titova N, Qamar MA, Chaudhuri KR. The Nonmotor Features of Parkinson's Disease. Int Rev Neurobiol 2017;132:33-54. [PMID: 28554413 DOI: 10.1016/bs.irn.2017.02.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]
5 Jobert M, Wilson FJ, Roth T, Ruigt GS, Anderer P, Drinkenburg WH, Bes FW, Brunovsky M, Danker-Hopfe H, Freeman J, van Gerven JM, Gruber G, Kemp B, Klösch G, Ma J, Penzel T, Peterson BT, Schulz H, Staner L, Saletu B, Svetnik V; IPEG Pharmaco-EEG Guidelines Committee. Guidelines for the recording and evaluation of pharmaco-sleep studies in man: the International Pharmaco-EEG Society (IPEG). Neuropsychobiology 2013;67:127-67. [PMID: 23548759 DOI: 10.1159/000343449] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
6 Vo Q, Gilmour TP, Venkiteswaran K, Fang J, Subramanian T. Polysomnographic Features of Sleep Disturbances and REM Sleep Behavior Disorder in the Unilateral 6-OHDA Lesioned Hemiparkinsonian Rat. Parkinsons Dis 2014;2014:852965. [PMID: 25610706 DOI: 10.1155/2014/852965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cusmano DM, Hadjimarkou MM, Mong JA. Gonadal steroid modulation of sleep and wakefulness in male and female rats is sexually differentiated and neonatally organized by steroid exposure. Endocrinology 2014;155:204-14. [PMID: 24189140 DOI: 10.1210/en.2013-1624] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
8 Paterson LM, Nutt DJ, Wilson SJ. Sleep and its disorders in translational medicine. J Psychopharmacol 2011;25:1226-34. [PMID: 21490119 DOI: 10.1177/0269881111400643] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
9 Fifel K, Piggins H, Deboer T. Modeling sleep alterations in Parkinson's disease: How close are we to valid translational animal models? Sleep Medicine Reviews 2016;25:95-111. [DOI: 10.1016/j.smrv.2015.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
10 Rothman SM, Mattson MP. Sleep disturbances in Alzheimer's and Parkinson's diseases. Neuromolecular Med 2012;14:194-204. [PMID: 22552887 DOI: 10.1007/s12017-012-8181-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
11 Snyder LR, Marler TE. Rethinking cycad metabolite research. Commun Integr Biol 2011;4:86-8. [PMID: 21509189 DOI: 10.4161/cib.4.1.14084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Cusmano DM, Mong JA. In utero exposure to valproic acid changes sleep in juvenile rats: a model for sleep disturbances in autism. Sleep 2014;37:1489-99. [PMID: 25142574 DOI: 10.5665/sleep.3998] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
13 Iyer V, Vo Q, Mell A, Chinniah S, Zenerovitz A, Venkiteswaran K, Kunselman AR, Fang J, Subramanian T. Acute levodopa dosing around-the-clock ameliorates REM sleep without atonia in hemiparkinsonian rats. NPJ Parkinsons Dis 2019;5:27. [PMID: 31815176 DOI: 10.1038/s41531-019-0096-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Spencer PS, Palmer VS, Kisby GE. Western Pacific ALS-PDC: Evidence implicating cycad genotoxins. J Neurol Sci 2020;419:117185. [PMID: 33190068 DOI: 10.1016/j.jns.2020.117185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Bezard E, Fernagut P. Premotor parkinsonism models. Parkinsonism & Related Disorders 2014;20:S17-9. [DOI: 10.1016/s1353-8020(13)70007-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
16 Medeiros DC, Lopes Aguiar C, Moraes MFD, Fisone G. Sleep Disorders in Rodent Models of Parkinson's Disease. Front Pharmacol 2019;10:1414. [PMID: 31827439 DOI: 10.3389/fphar.2019.01414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Hunt J, Coulson EJ, Rajnarayanan R, Oster H, Videnovic A, Rawashdeh O. Sleep and circadian rhythms in Parkinson's disease and preclinical models. Mol Neurodegener 2022;17:2. [PMID: 35000606 DOI: 10.1186/s13024-021-00504-w] [Reference Citation Analysis]
18 McDowell K, Chesselet MF. Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 2012;46:597-606. [PMID: 22236386 DOI: 10.1016/j.nbd.2011.12.040] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 10.4] [Reference Citation Analysis]
19 Le W, Sayana P, Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics 2014;11:92-110. [PMID: 24158912 DOI: 10.1007/s13311-013-0234-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
20 Liu C, Xue Y, Liu MF, Wang Y, Chen L. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential. Neurochem Int 2020;138:104754. [PMID: 32422324 DOI: 10.1016/j.neuint.2020.104754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]